PROGRAMME Poster Presentations
Poster Session 01: Helicobacter 01
P01.01.
Comparison Of Standard Triple Therapy With Or Without Bismuth As An Initial Treatment For Helicobacter Pylori Infection
Seok-ryeol Choi, Busan, Korea, Republic of
P01.02.
Identification Of Potentially New Antiinfectives Against H. Pylori By Repurposing FDA-Approved Drugs
Dietmar Pfeiffer, Munich, Germany
P01.03.
The Efficacy Of Rifabutin-Based Helicobacter Pylori Eradication Regimen
Yuri Kim, Daegu, Korea, Republic of
P01.04.
Duodenogastric Reflux In helicobacter pylori infection And Re-Infection
Adriana Barrios, Quetzaltenango, Guatemala
P01.05.
The Widely Used 15% Clarithromycin Resistance Cut-Off Rule Fails To Predict H. Pylori Treatment Success Or Failure And Should Be Abandoned.
Selvi Thirumurthi, Houston, United States
P01.06.
Helicobacter Suis infection Induced Xenophagy And Apoptosis In Mouse Parietal Cells
Masahiko Nakamura, Isehara, Japan
P01.07.
Changes Of Metabolic Profile After Eradication Of helicobacter Pylori
Moon Kyung Joo, Seoul, Korea, Republic of
P01.08.
New In-Office H. Pylori Detection Device.
Miltiadis Moutzoukis, Ioannina, Greece
P01.09.
Brazilian Registry On H. Pylori Management(Hp-Brazilreg) Analysis Of 835 First-Line Empiric Treatments
Luiz Coelho, Belo Horizonte, Brazil
P01.10.
Brazilian Registry On H. Pylori Management (Hp-Brazilreg) Analysis Of 300 Empiric Second-Line And Rescue Treatments
Luiz Coelho, Belo Horizonte, Brazil
P01.11.
Effectiveness Of First-Line Treatment For H. Pylori Infection In Israel: Results From The European Registry On H. Pylori Management (Hp-EuReg).
Doron Boltin, Petah Tikva, Israel
P01.12.
Prescriptions And Effectiveness Are Influenced By Indications For Helicobacter Pylori Investigation: European Registry On H. Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
Poster Session 02: Helicobacter 02
P02.01.
Culture-Based Susceptibility-Guided Tailored Versus Empirical Concomitant Therapy As First-Line Helicobacter Pylori Treatment: A Randomized Clinical Trial
Byung-Hoon Min, Seoul, Korea, Republic of
P02.02.
Helicobacter Pylori Status Is Not Predictive Of Periodontal Disease
Marko Nikolic, Zagreb, Croatia
P02.03.
Diminishing Of Helicobacter Pylori Adhesion To Gastric Tissue Of Cavie Porcellus Inoculated With These Bacteria Due To Previous Inoculation With BCG Vaccine Mycobacteria
Weronika Gonciarz, Lódz, Poland
P02.04.
Spray Dried Ph Sensitive Chitosan Microparticles Loaded With Mycobacterium Bovis - BCG Intended For Supporting Treatment Of Helicobacter Pylori Infection
Weronika Gonciarz, Lódz, Poland
P02.05.
Assessment Of The Prevalence Of Significant Endoscopic Lesions In Patients Over 18 Years With Helicobacter Pylori Infection In A Center In North-East Romania
ELENA POPOVICI, BACAU, Romania
P02.06.
Prescribing Trends Of Helicobacter Pylori Eradication Treatment In Irish Primary Care From 2015 To 2019: A Cross-Sectional Analysis
Marta Dobric, Dublin, Ireland
P02.07.
Usefulness Of Antimicrobial Susceptibility Testing In The Eradication Treatment Of Patients With Two Or More Failed Helicobacter Pylori Eradication Treatments.
Mariko Hojo, Tokyo, Japan
P02.08.
Empirical First Line H. Pylori Eradication Therapy In Italy From 2013 To 2023: Effectiveness Results From The European Registry On H. Pylori Management (Hp-Eu-Reg)
Matteo Pavoni, Carrara, Italy
P02.09.
Change Of Treatment Pathway Of Helicobacter Pylori Infection After The Guideline Update: A Distributed Network Analysis Of Multi-Center Databases Using Common Data Model
Young woo Chae, Seoul, Korea, Republic of
P02.10.
Withdrawn
P02.11.
Effectiveness Of First-Line Empirical Treatment In Portugal: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Maria Viegas, Coimbra, Portugal
Poster Session 03: Helicobacter 03
P03.01.
First-Line Prescription Patterns And Eradication Rates In Ireland Over A 10-Year Period: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Sinead Smith, Dublin, Ireland
P03.02.
Prevalence Of Primary Clarithromycin Resistance In Patients Infected With Helicobacter Pylori In Europe In The Last Four Decades
Olga Nyssen, Madrid, Spain
P03.03.
Seroprevalence Of H.Pylori In 25-64 Years Old Population In Lithuania
Limas Kupcinskas, Kaunas, Lithuania
P03.04.
Status Of The Helicobacter Pylori Screening At Our Institution Over Four Years
Kumiko Ueda, Tokyo, Japan
P03.05.
Comparative Efficacy & Safety Of Potassium-Competitive Acid Blocker (P-CAB) Based Dual, Triple And Quadruple Regimens For First Line H. Pylori Infection Treatment: A Systematic Review And Network Meta-Analysis.
Theodore Rokkas, Athens, Greece
P03.06.
Relationship Between The Presence Of Antibodies To The CAGA Of H.Pylori And The Stage Of Chronic Gastritis According To The OLGA System
Dmitry Bordin, Moscow, Russian Federation
P03.07.
Idiopathic Gastric Antral Ulcers
koji nakamichi, hukuoka, Japan
P03.08.
Real-World Efficacy Of Second-Line Therapies For helicobacter Pylori: A Population-Based Study
Wai Keung Leung, Hong Kong, Hong Kong
P03.09.
MUC5AC Expression In The Gastric Mucosa Of Helicobacter Pylori Positive Gastritis - A Systematic Review And Meta-Analysis
Yaron Niv, Ariel, Israel
P03.10.
Helicobacter Pylori Infection Recurrence In Developed Versus Developing Countries - A Systematic Review And Meta-Analysis
Yaron Niv, Ariel, Israel
P03.11.
Trends In The Prescription Of Eradication Treatments And Their Effectiveness In Naïve Patients Over 11 Years (2013-2023) In Europe: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P03.12.
Empirical Second-Line Treatments In Europe: Data From 9,000 Cases From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
Poster Session 04: Helicobacter 04
P04.01.
Effectiveness And Safety Of 1St Line Anti-H.Pylori Therapy In Ukraine (According To Hp-EuReg Data)
Olga P. Nyssen, Madrid, Spain
P04.02.
Helicobacter Pylori First-Line Empirical Therapy Effectiveness And Its Relationship To Antibiotic Consumption In The Community: Data From The European Registry On H. Pylori Management (Hp-EuReg).
Olga P. Nyssen, Madrid, Spain
P04.03.
Experience With Single-Capsule Bismuth Quadruple Therapy In 11,000 Patients From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P04.04.
Effectiveness Of Single-Capsule Bismuth Quadruple Re-Treatment After Previous Failure With The Same Therapy: Results From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P04.05.
Non-Bismuth Quadruple Concomitant Treatment For Helicobacter Pylori Eradication: Systematic Review And Meta-Analysis
Pablo Parra, Madrid, Spain
P04.06.
Empirical First-Line Prescriptions And Effectiveness Trends In Azerbaijan In The Period 2020-2023: Results From The European Registry On H. Pylori Management (Hp-EuReg)
Gulustan Babayeva, Baku, Azerbaijan
P04.07.
Helicobacter Pylori First- And Second-Line Empirical Prescriptions And Effectiveness In Lithuania During The Years 2013-2023: Analysis Of The European Registry On H. Pylori Management (Hp-EuReg)
Paulius Jonaitis, Kaunas, Lithuania
P04.08.
Prescriptions And Effectiveness Of 3,351 Empirical Rescue Therapies On Third And Subsequent Lines: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P04.09.
Updating Primary Antibiotic Resistance In H. Pylori Strains
Matteo Pavoni, Bologna, Italy
P04.10.
Gastric Acid Inhibition With Esomeprazole Or Pantoprazole In The Sequential Therapy For H. Pylori Eradication In Clinical Practice
Matteo Pavoni, Bologna, Italy
P04.11.
Fourteen-Day Amoxicillin Or Tetracycline Containing Bismuth Quadruple Therapy Versus 14-Day Metronidazole Based Triple Therapy As A First-Line Treatment For Clarithromycin Resistant Helicobacter Pylori Infection: A Multicenter Randomized Controlled Trial
Samryong Jee, Busan, Korea, Republic of
P04.12.
The Effectiveness Of First And Second Line Therapy In The Treatment Of Helicobacter Pylori - Data From A Greek Hospital.
Athanasios Kontos, Athens, Greece
P04.13.
Helicobacter Pylori Infection In Symptomatic Vietnamese Children: Prevalence, Antibiotic Resistance, And Treatment Implications
Tu Nguyen, Ho Chi Minh City, Viet Nam
Poster Session 05: Helicobacter 05
P05.01.
Genomic Analysis Of Signaling Pathways During Multistep Processes Of Helicobacter Pylori-Induced Gastric Cancer Development
Sung Eun Kim, Busan, Korea, Republic of
P05.02.
Evaluation Of The Effectiveness And Safety Of Helicobacter Pylori Empirical Eradication Regimens In Switzerland: An Interim Analysis With Data From The European Registry On H. Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P05.03.
Distribution Of Antimicrobial MICs For Helicobacter Pylori Strains Over A Six-Year Period In Korean Patients From Seoul, Korea
Jung Mogg Kim, Seoul, Korea, Republic of
P05.04.
Screening And Eradication Of helicobacter Pylori for Junior High School Students In Japan. Nationwide Survey For Local Governments Regarding Conducted Status And Methods.
Masumi Okuda, Nishinomiya, Japan
P05.05.
The Second Irish Helicobacter Pylori Working Group Consensus For The Diagnosis And Treatment Of Helicobacter Pylori Infection In Adult Patients In Ireland.
Sinead Smith, Dublin, Ireland
P05.06.
Preliminary Results Of The Follow-Up Of A GISTAR Study Participant Cohort
Danute Razuka-Ebela, Riga, Latvia
P05.07.
Use Of Self-Administered Rapid Stool Antigen Test For Monitoring After H. Pylori Eradication Therapy
Wai Keung Leung, Hong Kong, Hong Kong
P05.08.
Eradication Of Helicobacter Pylori Infection With The Help Of Autoprobiotics
Galina Alekhina, St-Petersburg, Russian Federation
P05.09.
Effectiveness Of The First-Line Eradication Therapy In 14 Cities In Russia: Results For The Period 2013-2022 Of The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Dmitriy Bordin, Moscow, Russian Federation
P05.10.
The Potential Use Of helicobacter Pylori Phages - What Do We Know So Far
Rute Ferreira, Braga, Portugal
P05.11.
Effectiveness Of Rebamipide-Containing First-Line Empirical Eradication Therapy In Russia: Results From The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Dmitry Bordin, Moscow, Russian Federation
P05.12.
The YAP/TAZ-Tead Pathway Controls Cytolethal Distending Toxin-Induced Dna Damage And Nuclear Remodeling In Intestinal Epithelial Cells
Lamia AZZI-MARTIN, Bordeaux, France
Poster Session 06: Helicobacter 06
P06.01.
Increased Infiltration Of CD4+IL-17A+FOXP3+ T Cells In Helicobacter Pylori-Induced Gastritis
Yixian Guo, Shanghai, China
P06.02.
Helicobacter Pylori Associated Lesions Of The Upper Gastrointestinal Tract In Patients With Esophageal Dysphagia
Rashad Hasanov, Baku, Azerbaijan
P06.03.
Differential Accuracy Of Serology Test For The Diagnosis Of H. Pylori According To Age And Gastric Atrophy In A Large Scale Study
Jyh-Ming Liou, Taipei, Taiwan
P06.04.
Optimization Of Minocycline-Containing Bismuth Quadruple Therapy For Helicobacter Pylori Rescue Treatment: A Real-World Evidence Study
Hong Lu, Shanghai, China
P06.05.
Is Helicobacter Pylori Status Associated With Metachronous Gastric Cancer In Elderly Patients After Endoscopic Resection For Early Gastric Cancer?
Jong Yeul Lee, Goyang, Korea, Republic of
P06.06.
An Update Of The Helicobacter Pylori Diagnostic Tests And Indications For Treatment From The Latin American Registry On Helicobacter Pylori Management (Hp-LATAMreg).
Arnoldo Riquelme, Santiago, Chile
P06.07.
Interplay Of C-Terminal EPIYA-Repeats And NikS-Mediated Post-Transcriptional Regulation Of CagA mRNA
Fabian Lemos, Vitória da Conquista, Brazil
P06.08.
Stool Antigen Test For Helicobacter Pylori Infection In Adults: A Meta-Analysis Of Diagnostic Test Accuracy
Fabrício Freire de Melo, Vitória da Conquista, Brazil
P06.09.
Most Frequent Helicobacter Pylori first-Line Empirical Eradication Therapies: Data From The Latin American Registry On H. Pylori Management (Hp-LATAMreg).
Arnoldo Riquelme, Santiago, Chile
P06.10.
Gastroprotective And Cytotoxic Effects Of Diacetylcurcumin And Its Metallic Derivatives
Almanelly Agabo-Martínez, Ciudad de Mexico, Mexico
P06.11.
World'S First Isolation Culture And Eradication Therapy Of Helicobacter Ailurogastricus In Human Patients
Masaya Sano, Kanagawa, Japan
P06.12.
Real-World Data At A High Volume Center In Republic Of Korea <: > The 1St-Line Regimens For The Eradication Of Helicobacter Pylori
Sung Kwan Shin, Seoul, Korea, Republic of
Poster Session 07: Helicobacter 07
P07.01.
Differences Between Japan And Lithuania In Gastric Mucosal Damage And Gastric Cancer Profile Associated With H. Pylori Infection. A Lithuania-Japan International Collaborative Study.
Hideki Mori, Tokyo, Japan
P07.02.
Validation Of A Nearly Commercially Available In-House Selective Medium For The Isolation Of Helicobacter Pylori From Gastric Biopsies.
Véronique MIENDJE DEYI, Brussels, Belgium
P07.03.
Withdrawn
P07.04.
Pcr-Guided Tailored Therapy In The Eradication Of Helicobacter Pylori: Experience From The European Registry On H. Pylori Management (Hp-EuReg)
Vladimir Milivojevic, Belgrade, Serbia
P07.05.
Molecular Resistance Of Helicobacter Pylori To Clarithromycin And Levofloxacin In Naive Patients In Moscow
Larisa Tsapkova, Moscow, Russian Federation
P07.06.
Antibiotic Resistance Evaluation Among Pcr-Tested Helicobacter Pylori Positive Patients: Results From The European Registry On H. Pylori Management (Hp-EuReg)
Vladimir Milivojevic, Belgrade, Serbia
P07.07.
Designer Non-Antibiotic Drug To Combat Helicobacter Pylori In The Age Of Antibiotic Resistance
Nicola Jones, Toronto, Canada
P07.08.
Effect Of Helicobacter Pylori Treatment On Clinical Outcomes In Patients With Gastrointestinal Bleeding Within 12 Months After Percutaneous Coronary Intervention - A Nationwide Population-Based Study
Beom Jin Kim, Seoul, Korea, Republic of
P07.09.
Cost Effectiveness Analysis Of Screening And Treatment Helicobacter Pylori Strategy For Preventing Gastric Cancer In Germany
Tianjun Song, Munich, Germany
P07.10.
Excellent Eradication Rate Of Once-Daily Vonoprazan, Levofloxacin, Clarithromycin-Mr, And Bismuth For H. Pylori Infection In High Clarithromycin And Metronidazole Resistance Area: A Prospective Randomized Study (Once-Vono Trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
P07.11.
Withdrawn
P07.12.
The Role Of Paraoxonase 1 In Helicobacter Induced Gastritis
Sung Soo Kim, Uijongbu, Korea, Republic of
Poster Session 08: Helicobacter 08
P08.01.
Usefullness Of Helicobacter Pylori Salivary Antigen Test
Ayoung Lee, Ansan-si, Korea, Republic of
P08.02.
Withdrawn
P08.03.
First-Line Empirical Therapy In The Uk: Interim Analysis From Data Of The European Registry On Helicobacter Pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P08.04.
Withdrawn
P08.05.
Epithelial BMP Signaling Controls Tissue Response To Helicobacter Pylori Infection
Giulia Beccaceci, Berlin, Germany
P08.06.
Hydrogen Sulfide Donor Diminishes The Helicobacter Pylori-Induced Gastric Fibroblast Activation, Reducing The Risk Of Gastric Cancer Development
Gracjana Krzysiek-Maczka, Krakow, Poland
P08.07.
The Influence Of Macrolide Exposure On Tailored Helicobacter Pylori Eradication Therapy And Antibiotic Resistance Profiles: A Prospective Study Using The Drug Utilization Review System
Kee Don Choi, Seoul, Korea, Republic of
P08.08.
The Majority Of Complicated Peptic Ulcers Are Helicobacter Pylori-Associated, Among Which Clarithromycin-Resistant Infection Is Less Prevalent
Gábor Lotz, Budapest, Hungary
P08.09.
Validation Of An In-House Quantitative Real-Time Pcr Designed For Detection Of Helicobacter Pylori And Its Clarithromycin Resistance From Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Samples
Adrienn Biró, Budapest, Hungary
P08.10.
Differences In Success Rate Of Helicobacter Pylori Eradication According To Metronidazole Dose And Duration Of Use
So Young Byun, Seoul, Korea, Republic of
P08.11.
The Factors For Spontaneous Clearance Of Helicobacter Pylori After Subtotal Gastrectomy
So Young Byun, Seoul, Korea, Republic of
P08.12.
Withdrawn
Poster Session 09: Helicobacter 09
P09.01.
Helicobacter Pylori Carrying Prophages: Winners In Fitness And Virulence?
Joana Vital, Lisboa, Portugal
P09.02.
Helicobacter And Campylobacter Species Commonly Colonize The Intestines Of Swine
Zeli Shen, Cambridge, United States
P09.03.
Are They Jumping? Detecting Spontaneous Prophageinduction In Helicobacter Pylori Strains
Luís Tanoeiro, Lisboa, Portugal
P09.04.
Only In A Minority Of Patients With Autoimmune Atrophic Gastritis, Helicobacter Pylori-Specific Genes Are Detectable In Gastric Biopsies
Edith Lahner, Roma, Italy
P09.05.
A Discordance In The Prevalence Of H. Pylori Infection In Bile Between H. Pylori-Specific-Stool-Antigen Test And PCR
YOSHIHISA FUKUDA, Fukuoka, Japan
P09.06.
First-Line Helicobacter Pylori Empirical Treatment In The Czech Republic (2019-2024): Initial Insights From The European Registry On H. Pylori Management (Hp-EuReg)
Jan Krivinka, Olomouc, Czech Republic
P09.07.
Using An IL-10-/--B6.129 Mouse Model To Study Helicobacter Cinaedi Induced Cellulitis And Bacteremia
Zeli Shen, Cambridge, United States
P09.08.
The Cap-Independent Translation Of Survivin 5’ Untranslated Region (5’UTR) And Viral IRES Sequences Is Inhibited By H. Pylori Infection In Gastric Cells
Manuel Valenzuela Valderrama, santiago, Chile
P09.09.
A Blind Randomized Controlled Clinical Trial On The Efficacy And Safety Of Helicobacter Pylori Eradication Therapy In A South-European Country
Elisa Gravito-Soares, Coimbra, Portugal
P09.10.
Management Of Helicobacter Pylori Infection In Spain Beyond The European Registry. Results Of A Nationwide Survey
Olga Nyssen, Madrid, Spain
P09.11.
Novel Insights Into The Ph-Gating Mechanism Of The Inner Membrane Urea Channel HpUrei From Helicobacter Pylori
Andreas Horner, Linz, Austria
P09.12.
Helicobacter Pylori Base-Excision Restriction Enzyme In Gastric Cancer
Masaki Fukuyo, Chiba, Japan
Poster Session 10: Helicobacter 10
P10.01.
Novel Ligilactobacillus Salivarius Strains As Potential Probiotics In Helicobacter Pylori Eradication
Pirjo Spuul, Tallinn, Estonia
P10.02.
Helicobacter Pylori Treatment In Pakistan: Data From The Pakistan Registry On H. Pylori Management (Hp-PakistanReg)
Olga P. Nyssen, Madrid, Spain
P10.03.
Study Of Neutrophil Responses In Helicobacter Pylori Infection
Aristotelis Petris, Athens, Greece
P10.04.
The Case Of Gastric Metaplasia-Induced Duodenal Ulcer With H. Pylori Infection, Ultimately Leading To Death.
Jung Huh, Seoul, Korea, Republic of
P10.05.
Exploring General Practitioners' Practices And Perceptions Of helicobacter Pylori Infection
Charlene Deane, Dublin, Ireland
P10.06.
Withdrawn
P10.07.
Unveiling The Impact Of Chronic Gastric Helicobacter Infection On Mouse Hepatic Health
Sadia Khalid, Tallinn, Estonia
P10.08.
Exploring Cholesterol-Like Lipids As Bactericidal Decoys In The Fight Against Helicobacter Pylori
Ana Sofia Pinho, Porto, Portugal
P10.09.
Female Sex Is Associated With Helicobacter Pylori Clarithromycin Resistance And Treatment Failure
Thomas Butler, Dublin, Ireland
P10.10.
Efficacy Of Modified Levofloxacin-Based Regimen Following Bismuth Quadruple Therapy Failure For helicobacter Pylori Eradication In Korea
Ayoung Lee, Ansan, Korea, Republic of
P10.11.
Antimicrobial Resistance In Helicobacter Pylori Isolates: The Current Situation In Greece
Beatriz Martinez-Gonzalez, ATHENS, Greece
P10.12.
In Vitro Evaluation Of Antimicrobial Activity Against Helicobacter Pylori And Gastric Cytotoxicity Of Lipid Nanoparticles Coated With Chitosan
Bruna Almeida Furquim de Camargo, Araraquara, Brazil
Poster Session 11: Helicobacter 11
P11.01.
Glycosylation Landscape Of Gastric Patient-Derived Organoids As A Model To Study The Role Of helicobacter Pylori Binding
Liliana Santos-Ferreira, Porto, Portugal
P11.02.
Targeting The Urease Activity To Assist In The Prevention Of H. Pylori Infections
Raushan Kumar, Porto, Portugal
P11.03.
One Week Vs. Two Weeks Vonoprazan Based Triple Regimen For Eradication Of H.Pylori: A Double Blind Randomized Trial A Randomized Non-Inferiority Placebo Controlled Trial
Shahab Abid, Karachi, Pakistan
P11.04.
Use Of Previously Cryopreserved, Clinically Normal, Gptdelta Mice Ablates Natural And Experimental Typhlocolitis Noted With H. Mastomyrinus Infection In Gpt Deltamice With Apparent Immunodeficiency
Amanda Armijo, Cambridge, United States
P11.05.
Immunological Changes Determined By Bismuth Quadruple Therapy In Patients With Helicobacter Pylori Infection
Elisa Gravito-Soares, Coimbra, Portugal
P11.06.
Investigating The Role Of Efflux Pump Gene Expression In Antimicrobial Resistant Helicobacter Pylori
Stephen Molloy, Dublin, Ireland
P11.07.
Two Birds, One Set Of Biopsies: The Use Of Pcr For The Diagnosis Of Helicobacter Pylori And Detection Of Resistance Using Biopsies From Bedside Rapid Urease Tests.
Stephen Molloy, Dublin, Ireland
P11.08.
Helicobacter Pylori RNA Metabolism: Identifying Vulnerabilities For Novel Antimicrobial Drug Discovery To Combat Drug-Resistant Infections
Jakub Skibinski, Lodz, Poland
Poster Session 12: Microbiota 01
P12.01.
Bacteria-Derived Extracellular Vesicles In Liquid Biopsy: Potential Biomarkers For Gastric Cancer Detection
Jae Gyu Kim, Seoul, Korea, Republic of
P12.02.
A Microbiome Testing-Based Personalized Approach To Treat Post-Infectious Irritable Bowel Syndrome: A Pilot Study
William Fusco, Rome, Italy
P12.03.
Active Bacterial Assemblages Throughout The Gastrointestinal Tract In Patients With Dementia
Kerstin Schütte, Osnabrück, Germany
P12.04.
Fecal Microbiota Transplantation In Irritable Bowel Syndrome: A Meta-Analysis Of Randomized Controlled Trials And Prospective Cohort Studies
Ratha-korn Vilaichone, Pathumthani, Thailand
P12.05.
Comparison Of Different Microbiome Analysis Pipelines And Their Reproducibility In The Determination Of The Composition Of The Microbiome Of The Gastric Mucosa.
Konrad Lehr, Magdeburg, Germany
P12.06.
Healthy Reference Range In Microbiome Diagnostics
Christina Casén, Oslo, Norway
P12.07.
Second Generation Antipsychotics Induced Weight Gain Associated With Microbiome Changes In Children And Young Adults
Alexandra Oros, Cluj-Napoca, Romania
P12.08.
Efficacy And Safety Of Fecal Microbiota Transplantation For The Treatment Of Severe And Severe-Complicated Clostridioides Difficile Infection: Report From A Large-Volume Fmt Center
Andrea Severino, Rome, Italy
P12.09.
Clinical Relevance Of Positive Molecular Stool Testing For Intestinal Pathogens In Different Gastrointestinal Disorders
Pierluigi Frasca, Roma, Italy
P12.10.
Clostridioides Difficile Infection In Our Patients With Inflammatory Bowel Disease
Skender Telaku, Prishtina, Kosovo, Republic of
Poster Session 13: Microbiota 02
P13.01.
Oral, Fecal And Blood Microbial Signature In Esophageal Cancer
Ho-Kyoung Lee, Seoungnam-si, Korea, Republic of
P13.02.
Phageome Profiling In Human Samples With Low Microbial Biomass
Joana Pereira-Marques, Porto, Portugal
P13.03.
Skeletal Muscle-Gut Axis: Emerging Molecular And Microbial Mechanisms Of Sarcopenia In Experimental Models Of Inflammatory Bowel Disease
Sara Troisi, Roma, Italy
P13.04.
Sarcopenia And IBD: Exploring Molecular Mechanisms And Potential Pharmacological And Microbial Modulators In In Vitro Models Of Inflammatory Bowel Disease
Sara Troisi, Roma, Italy
P13.05.
Targeting Gut Microbiome To Treat Recurrent Urinary-Tract Infections From Gut Pathobionts: A Pilot Study
Tommaso Rozera, Roma, Italy
P13.06.
Optimization Of A Metagenomics Protocol To Analyze Microbial Signatures In Cell-Free DNA
Melissa Mendes-Rocha, Porto, Portugal
P13.07.
A Machine Learning Algorithm To Identify Hidden Microbiome Metabolites In The Stomach
Luisa Portela, Porto, Portugal
P13.08.
Efficacy And Safety Of Fecal Microbiota Transplantation For The Treatment Of Clostridioides Difficile Infection: A 10-Year Experience Of A Large-Volume FMT Center
Marcello Fiorani, Rome, Italy
P13.09.
Evaluation Of Epithelial Cell Response To Commensal Bacteria In The Intestinal Organoid Model Of Ulcerative Colitis Patients
Jurgita Skieceviciene, Kaunas, Lithuania
P13.10.
Personalized Autoprobiotic Supplements Improve The Serum Metabolome And Gut Microbiome In Patients With Irritable Bowel Syndrome
Galina Alekhina, Saint Petersburg, Russian Federation
Poster Session 14: Microbiota 03
P14.01.
Butyric Acid Counteracts H. Pylori Eradication-Induced Gut Microbiota Changes
Maria Markelova, Kazan, Russian Federation
P14.02.
"Influence Of Probiotics On Gut Microbiota In Genetic Mice Model Of Metabolic Syndrome"
Galina Alekhina, Saint-Petersburg, Russian Federation
P14.03.
Сomposition Of Intestinal Microbiocenosis In Children With Campylobacteriosis
Galina Alehina, Saint-Petersburg, Russian Federation
P14.04.
Autoprobiotics In Treatment Of Metabolic Syndrome
Galina Alekhina, Saint-Petersburg, Russian Federation
P14.05.
Therapeutic Modulation Of Gut Microbiome To Treat Immune-Checkpoint Inhibitors-Related Diarrhea And Colitis: Experience Of A Microbiome Clinic
Serena Porcari, Rome, Italy
P14.06.
Clostridium Difficile In Elderly: Challenging Topic
Rosa Ragozzino, Roma, Italy
P14.07.
Results Of A Regional Observational Retrospective Studies Of The Prevalence Of Small Intestinal Bacterial Overgrowth In Patients With digestive Diseases.
Valeriy Kryvy, Simferopol, Russian Federation
Poster Session 15: Cancer 01
P15.01.
Explainable Gastric Cancer Risk Prediction Of Machine Learning Based Models Trained On Data From Regular Health Check-Up Programs Of Screening Population
Ji Hyun Song, Seoul, Korea, Republic of
P15.02.
Withdrawn
P15.03.
The Feasibility Of Diagnostic Endoscopic Resection For Grade 1-2 Gastric Neuroendocrine Tumors: A Single-Institutional Retrospective Analysis
Cheol Woong Choi, Yangsan, Korea, Republic of
P15.04.
The Role Of Glycosylation In Gastric Carcinogenesis And Tumour Progression
Joana Gomes, Porto, Portugal
P15.05.
Inflammatory Markers And Recurrence Of Metachronous Tumors After Curative Resection Of Early Gastric Cancer
Moon Kyung Joo, Seoul, Korea, Republic of
P15.06.
Withdrawn
P15.07.
Withdrawn
P15.08.
Key Indicators For Global Gastric Cancer Endoscopic Screening Programs: A Systematic Review And Meta-Analysis
Jiayue Wang, Shanghai, China
P15.09.
Polymorphism Of Apoptosis Marker Genes In The Blood Of Indigenous People With Gastric Cancer In The Republic Of Tyva
Vladislav Tsukanov, Krasnoyarsk, Russian Federation
P15.10.
Index Of Gastric Epitheliocytes Proliferationin Helicobacter Pylori-Positive Patients With Atrophic Gastritis Depending On The Presence Of High Or Low Degree Dysplasia
Vladislav Tsukanov, Krasnoyarsk, Russian Federation
P15.11.
Higher Frequency Of Gastric Neoplasia In Advanced Chronic Liver Disease Patients In Comparison To A Healthy Population: Impact Of Screening Endoscopy In An Intermediate Risk Country
Miguel Martins, Porto, Portugal
P15.12.
Biopsies Sampling In Helicobacter Pylori Negative Patients: Is It Still Worthy?
Matteo Pavoni, Bologna, Italy
Poster Session 16: Cancer 02
P16.01.
Gastric Adenocarcinoma Recurrence After Endoscopic Submucosal Dissection For Early Gastric Cancer
Jeong Seop Moon, Busan, Korea, Republic of
P16.02.
Gastric Cancer Treatment Target Identified From An Accelerated Helicobacter-Induced Gastric Cancer Mouse Model
Marygorret Obonyo, San Diego, United States
P16.03.
The Role Of MUC13 In Gastric Cancer Cell Death Inhibition And Dysbiosis
Baptiste Oosterlinck, Antwerp, Belgium
P16.04.
Gastric Cancer Risk According To OLGA And OLGIM Stages In The Family Members Of Gastric Cancer Patients
Il Ju Choi, Goyang, Korea, Republic of
P16.05.
Size Does Matter: The Choice Of Treatment Modality For Superficial Esophageal Cancer
Ji Hoon Yoon, Seoul, Korea, Republic of
P16.06.
Withdrawn
P16.07.
Gastric Cancer Risk Among Immigrant And Socioeconomic Groups In The Netherlands
Duco Mülder, Rotterdam, Netherlands
P16.08.
Cell Extrusion Signatures In The Gastric Epithelium: A Crosstalk Between E-Cadherin And Filamin A
Soraia Melo, Porto, Portugal
P16.09.
E-Cadherin Dysfunction Modulates Structural Properties Of Nuclei In Gastric Cancer Cells
José Santos, Porto, Portugal
P16.10.
Clinical Significance Of Blood Urea Nitrogen As A Predictor Of Delayed Bleeding After Endoscopic Submucosal Dissection For Gastric Neoplasm
Beom Jin Kim, Seoul, Korea, Republic of
P16.11.
Optimized Endoscopic Surveillance Intervals For Detecting Progression Of Intestinal Metaplasia (IM): A Large Population-Based Study From Low Prevalence Area Of Gastric Cancer (IM-Surveillance Trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
Poster Session 17: Cancer 03
P17.01.
Withdrawn
P17.02.
Targeting The PI3K AKT mTORC1 Signaling Pathway In Gastric Cancer Stem Cells
Christine Varon, Bordeaux, France
P17.03.
Discovery And Validation Of Predictive Markers For Metachronous Gastric Cancer Development After Endoscopic Resection Of Early Gastric Cancer
Bokyung Kim, Seoul, Korea, Republic of
P17.04.
Microbiome-Derived Kynurenine Is A New Player In Gastric Cancer
Inês Castro, Porto, Portugal
P17.05.
Colorectal Cancer And Gut Microbiota: Possibilities Of Autoprobiotics In Complex Treatment
Galina Alekhina, St-Petersburg, Russian Federation
P17.06.
The Role Of Helicobacter Pylori, Cytotoxin-Associated Gene A CagA In Autophagic Pathways Of Gastric Epithelial Cells
Yong Chan Lee, Seoul, Korea, Republic of
P17.07.
Blood Plasma Cell-Free DNA Molecular Landscape In Gastric Cancer
Jurgita Skieceviciene, Kaunas, Lithuania
P17.08.
Elevated Bacterial Load And Attenuated Immune Response Observed In Tnfsf14-Deficient Mice Upon Helicobacter Pylori Infection.
Anja Mühlbauer, Munich, Germany
P17.09.
Targeted Screening For Gastric Cancer; A Combined Approach
Charlene Deane, Dublin, Ireland
P17.10.
How Well OLGA And OLGIM Stages Can Predict Gastric Cancer?
Paula Naļivaiko, Riga, Latvia
P17.11.
Helicobacter Pylori Infection Induces Gastric Precancerous Lesions And Persistent Expression Of Angpt2, Vegf-A And Tnf-A In A Mouse Model
Wendy Malespín-Bendaña, San Pedro de Montes de Oca, Costa Rica
P17.12.
Mycobiome Profile Alterations In Gastric Tissue Of Gastric Cancer Patients
Darja Nikitina, Kaunas, Lithuania